JP2025517476A5 - - Google Patents
Info
- Publication number
- JP2025517476A5 JP2025517476A5 JP2024569253A JP2024569253A JP2025517476A5 JP 2025517476 A5 JP2025517476 A5 JP 2025517476A5 JP 2024569253 A JP2024569253 A JP 2024569253A JP 2024569253 A JP2024569253 A JP 2024569253A JP 2025517476 A5 JP2025517476 A5 JP 2025517476A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- nectin
- immunoconjugate
- antibody fragment
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263345453P | 2022-05-25 | 2022-05-25 | |
| US63/345,453 | 2022-05-25 | ||
| PCT/EP2023/063912 WO2023227660A1 (en) | 2022-05-25 | 2023-05-24 | Nectin-4 binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517476A JP2025517476A (ja) | 2025-06-05 |
| JP2025517476A5 true JP2025517476A5 (enExample) | 2026-04-27 |
Family
ID=86710807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024569253A Pending JP2025517476A (ja) | 2022-05-25 | 2023-05-24 | ネクチン－４結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250297004A1 (enExample) |
| EP (1) | EP4532020A1 (enExample) |
| JP (1) | JP2025517476A (enExample) |
| KR (1) | KR20250017209A (enExample) |
| CN (1) | CN119233994A (enExample) |
| AU (1) | AU2023276860A1 (enExample) |
| CA (1) | CA3245954A1 (enExample) |
| IL (1) | IL316140A (enExample) |
| MX (1) | MX2024014288A (enExample) |
| TW (1) | TW202411251A (enExample) |
| WO (1) | WO2023227660A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4096717B1 (en) | 2020-01-31 | 2024-12-11 | Innate Pharma | Treatment of cancer |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN121511098A (zh) * | 2023-06-01 | 2026-02-10 | 拜斯科技术开发有限公司 | 对nectin-4具有特异性的双环肽配体及其用途 |
| WO2025141316A1 (en) * | 2023-12-27 | 2025-07-03 | Intocell, Inc. | Antibody drug conjugates comprising camptothecin derivatives and uses thereof |
| TW202535960A (zh) * | 2024-01-08 | 2025-09-16 | 大陸商上海橙帆醫藥有限公司 | 抗體及其藥物偶聯物和用途 |
| CN120383674A (zh) * | 2024-01-26 | 2025-07-29 | 鲁南新时代生物技术有限公司 | 一种Nectin-4抗体及其应用 |
| KR20250177512A (ko) * | 2024-06-14 | 2025-12-24 | 삼성바이오에피스 주식회사 | 신규한 항-넥틴-4 항체 및 이의 용도 |
| WO2025261506A1 (zh) * | 2024-06-21 | 2025-12-26 | 信达生物制药(苏州)有限公司 | 抗Nectin-4抗体以及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| EA003398B1 (ru) | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| JP4638225B2 (ja) | 2002-05-30 | 2011-02-23 | ザ スクリプス リサーチ インスティテュート | 銅を触媒とするアジドとアセチレンのライゲーション |
| WO2004043880A2 (de) | 2002-11-11 | 2004-05-27 | Basf Aktiengesellschaft | Verfahren zur herstellung von 2-keto-l-gulonsäure-c4-c10-alkylestern |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| WO2005085251A1 (en) | 2004-03-01 | 2005-09-15 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| EP2222341B1 (en) | 2007-11-21 | 2015-02-25 | University Of Georgia Research Foundation, Inc. | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| US8961967B2 (en) | 2009-11-30 | 2015-02-24 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| WO2011121453A2 (en) | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
| JP5875083B2 (ja) | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | 増殖性疾患治療用ピロロベンゾジアゼピン |
| MX347954B (es) | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| JP5826863B2 (ja) | 2011-02-15 | 2015-12-02 | イミュノジェン・インコーポレーテッド | 細胞傷害性ベンゾジアゼピン誘導体 |
| EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| NZ758049A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| CN107106701B (zh) | 2014-10-03 | 2020-11-06 | 西纳福克斯股份有限公司 | 磺酰胺接头、其缀合物及制备方法 |
| EP3218009B1 (en) | 2014-10-14 | 2021-04-07 | Polytherics Limited | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
| CN110392697A (zh) | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | 对nectin-4具有特异性的抗体及其用途 |
| JP7381478B2 (ja) | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド－薬物－複合体 |
| CA3128571A1 (en) | 2019-03-19 | 2020-09-24 | Paul Scherrer Institut | Transglutaminase conjugation method with a glycine based linker |
| EP4096717B1 (en) * | 2020-01-31 | 2024-12-11 | Innate Pharma | Treatment of cancer |
| EP4208259A2 (en) * | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
-
2023
- 2023-05-24 JP JP2024569253A patent/JP2025517476A/ja active Pending
- 2023-05-24 AU AU2023276860A patent/AU2023276860A1/en active Pending
- 2023-05-24 IL IL316140A patent/IL316140A/en unknown
- 2023-05-24 CN CN202380039589.3A patent/CN119233994A/zh active Pending
- 2023-05-24 US US18/867,898 patent/US20250297004A1/en active Pending
- 2023-05-24 KR KR1020247037990A patent/KR20250017209A/ko active Pending
- 2023-05-24 CA CA3245954A patent/CA3245954A1/en active Pending
- 2023-05-24 EP EP23729061.4A patent/EP4532020A1/en active Pending
- 2023-05-24 WO PCT/EP2023/063912 patent/WO2023227660A1/en not_active Ceased
- 2023-05-25 TW TW112119460A patent/TW202411251A/zh unknown
-
2024
- 2024-11-19 MX MX2024014288A patent/MX2024014288A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025517476A5 (enExample) | ||
| KR102923527B1 (ko) | 생체활성 분자 접합체, 이의 제조 방법 및 용도 | |
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| ES2804614T3 (es) | Conjugados de polipéptidos manipulados usando transglutaminasa | |
| AU2020338481B2 (en) | Targeted dendrimer conjugates | |
| JP2024501121A5 (enExample) | ||
| JP2016521256A (ja) | 生物活性分子、そのコンジュゲート、及び治療用途 | |
| CN106795203A (zh) | 用于抗体药物缀合物的稳定性调节接头 | |
| CN106661123A (zh) | 抗‑cd22抗体‑药物缀合物及其使用方法 | |
| BR112021010364A2 (pt) | Composições farmacêuticas que compreendem conjugados de anticorpo-fármaco anti-191p4d12 e métodos de uso das mesmas | |
| KR20250137203A (ko) | 항체 약물 접합체 | |
| WO2017196764A1 (en) | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses | |
| JP2025535447A (ja) | 抗体－薬物コンジュゲート、その調製方法および使用 | |
| KR20250084935A (ko) | 링커-페이로드 화합물, 접합체 및 이의 응용 분야 | |
| US20240269313A1 (en) | Conjugates comprising a phosphorus(v) moiety and a drug | |
| US20250127916A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| US20250195675A1 (en) | New antibody-drug conjugate as well as methods of production and uses thereof | |
| TW202610635A (zh) | 多特異性多藥物之抗體藥物結合物 | |
| WO2026018064A1 (en) | Multispecific multi-drug antibody-drug conjugates | |
| WO2026011073A1 (en) | Antibody drug conjugates | |
| KR20250148459A (ko) | 항-cntn4 항체를 포함하는 컨쥬게이트 및 이의 용도 |